Each vial contains: Ceftriaxone Sodium, USP, equivalent to Ceftriaxone 1 g, Tazobactam Sodium equivalent to Tazobactam 125 mg, Supplied with 10 ml sterile Water for Injection.
For the treatment of patients with community acquired pneumonia and lower respiratory tract infections.
Ceftriaxone is a 2-aminothiazolyl methoxyimino third-generation cephalosporin derivative. Ceftriaxone, a bactericidal antimicrobial, inhibits bacterial wall synthesis of actively dividing cells by binding to one or more penicillin bind proteins (PBPs). These proteins are associated with the bacterial cell membrane and probably serve as synthesis. Tazobactam is a penicillinate sulphone, structurally related to sulbactam. Being a beta- lactamase inhibitor, it is synergistic with many beta-lactamase-labile drugs such as penicillins and cephalosporins.
Adults and children over 12 years: The usual adult dose is 1 - 2 g given once a day (or in equally divided doses twice a day), depending upon the severity of the infection. For severe infections, 2–4 g daily, normally as a single dose every 24 hours. In neonates: A daily dose of 20–50 mg/ kg body weight, not to exceed 50 mg/ kg. Infants and Children Aged up to 12 Years: Standard therapeutic dosage: 50-75 mg/ kg body weight once daily.
Contraindicated in patients with known hypersensitivity to beta-lactam antibiotics. In patients hypersensitive to penicillin, the possibility of allergic cross-reactions should be borne in mind.
Do not use diluents containing calcium, such as Ringer’s solution or Hartmann’s solution, to reconstitute ceftriaxone sodium vials or to further dilute a reconstituted vial for IV administration because a precipitate can be formed. Alterations in prothrombin times have occurred rarely in patients treated with ceftriaxone sodium. If Clostridium difficle-associated diarrhoea (CDAD) is suspected or confirmed, ongoing antibiotic use not directed against C. difficle may need to be discontinued.
Pregnancy Category B. Low concentrations of ceftriaxone are excreted in human milk. Caution should be exercised when administered to a nursing woman.
No interference with the action or increase in nephrotoxicity of aminoglycosides has been observed during simultaneous administration with ceftriaxone/tazobactam. The elimination of ceftriaxone/tazobactam is not altered by probenecid.
Rash, superinfections of various sites with yeasts, fungi or other resistant organisms are possible, Eosinophilia, thrombocytosis and leucopenia, Anaphylactic (e.g. bronchospasm) and anaphylactoid reactions, loose stools or diarrhoea, nausea, vomiting and allergic dermatitis.
Doctors
Nurses
PRODUCT DETAILS VIEW ALL PRODUCTS